Embecta Corp (EMBC) Peer Comparison
$5.19
$0.14
(2.67%)
As on 31-Aug-2026 14:36EDT
Market cap
$286 Mln
Revenue (TTM)
$1,019 Mln
P/E Ratio
3.4
P/B Ratio
2.6
Div. Yield
9.3 %
Edit
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
286 | 12,753 | 10,906 | 9,948 | 9,762 |
Revenue ($ Mln) |
1,019 | 1,505 | 613 | 785 | 2,589 |
Net Profit ($ Mln) |
87.50 | 160.59 | -188.05 | 41.54 | 222.40 |
Net Margin (%) |
8.59 | 10.67 | -30.68 | 5.29 | 8.59 |
RoE (%) |
-- | 10.86 | -28.10 | 1.97 | 3.04 |
Price to Earnings |
3.44 | 79.35 | -- | 251.81 | 44.47 |
Price-To-Book |
2.61 | 8.41 | 16.38 | 4.86 | 1.26 |
Income Statement ($ Mln)
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,018.70 | 1,504.87 | 612.84 | 785.10 | 2,589.30 |
|
Cost of Revenue
|
408.60 | 483.98 | 127.96 | 384.30 | 1,245.50 |
|
Gross Profit
|
679.50 | 942.44 | 393.22 | 347.62 | 1,343.60 |
|
Operating Expenses
|
357.00 | 833.56 | 565.37 | 335.50 | 1,108.90 |
|
Operating Profit (EBIT)
|
253.10 | 187.34 | -80.49 | 65.30 | 235.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
125.00 | 203.83 | -192.83 | 52.15 | 350.40 |
|
Provision for Tax
|
37.50 | 43.24 | -4.79 | 10.61 | 128.00 |
|
Profit after Tax (Net Income)
|
87.50 | 160.59 | -188.05 | 41.54 | 222.40 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 93.19 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-612.70 | 1,530.77 | 682.49 | 2,112.03 | 7,173.90 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
1,458.20 | 210.18 | 135.71 | 705.49 | 2,116.80 |
|
Current Liabilities
|
419.80 | 233.78 | 102.33 | 132.66 | 961.30 |
|
Total Liabilities
|
1,090.90 | 1,826.52 | 893.49 | 2,949.70 | 10,576.50 |
Assets ($ Mln)
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
560.20 | 630.60 | 404.74 | 1,749.63 | 7,231.50 |
|
Current Assets
|
705.10 | 1,344.12 | 515.78 | 1,200.55 | 3,020.50 |
|
Total Assets
|
1,090.90 | 1,826.52 | 893.49 | 2,949.70 | 10,576.50 |
|
Total Debt*
|
1,501.70 | 212.71 | 102.84 | 690.94 | 1,203.70 |
|
Net Current Assets
|
285.30 | 1,110.35 | 413.45 | 1,067.90 | 2,059.20 |
Cashflow ($ Mln)
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
191.70 | 238.66 | -46.34 | 117.42 | 532.20 |
|
Cash Flow from Investing Activities
|
-9.30 | -404.59 | -77.61 | -298.47 | -189.70 |
|
Cash from Financing Activities
|
-226.70 | 26.53 | 11.89 | -15.21 | -283.20 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.57 | 11.76 | -22.53 | 1.79 | 8.98 |
|
ROE (%)
|
-13.73 | 10.86 | -28.10 | 1.97 | 3.04 |
|
ROA (%)
|
5.61 | 7.95 | -18.00 | 1.36 | 2.02 |
|
EBIT Margin (%)
|
21.76 | 13.63 | -30.58 | 9.87 | -5.99 |
|
Net Margin (%)
|
8.59 | 10.67 | -30.68 | 5.29 | 8.59 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-7.60 | 17.55 | 41.55 | 16.49 | 1.37 |
|
EBIT Growth (%)
|
5.32 | 17.49 | -116.42 | 920.91 | -131.06 |
|
Net Profit Growth (%)
|
5.55 | 8.72 | -102.66 | 400.42 | -30.32 |
|
EPS Growth (%)
|
4.93 | 8.12 | -96.88 | 394.30 | -29.66 |
|
Book Value Growth (%)
|
8.52 | 17.33 | -12.65 | 2.16 | 2.19 |
Valuation Ratios
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
8.71 | 68.93 | -34.59 | 189.42 | -- |
|
Price / Book Value
|
-1.28 | 8.58 | 9.90 | 4.40 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
6.91 | 53.25 | -43.50 | 55.90 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-2.15 | 0.00 | 0.00 | 0.26 | 0.11 |
|
Short term debt to equity ratio
|
-0.24 | 0.01 | 0.00 | 0.01 | 0.06 |
|
Current Ratio
|
1.68 | 5.75 | 5.04 | 9.05 | 3.14 |
|
Quick Ratio
|
1.17 | 3.86 | 4.46 | 7.64 | 2.33 |
|
Interest Coverage
|
2.29 | 157.91 | -38.31 | 3.36 | 8.18 |
Operating Efficiency Ratios
| Embecta Corp (EMBC) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.89 | 12.65 | 22.67 | 20.09 | 17.06 |
|
Asset Turnover
|
0.65 | 0.74 | 0.59 | 0.26 | 0.24 |
|
Receivable days
|
67.09 | 46.54 | 60.95 | 72.41 | 65.39 |
|
Inventory Days
|
159.48 | 331.92 | 193.84 | 146.53 | 221.09 |
|
Payable days
|
75.25 | 26.16 | 60.19 | 29.05 | 37.02 |
|
Cash Conversion Cycle
|
151.32 | 352.30 | 194.60 | 189.88 | 249.46 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
